Rezvilutamide Combined With Radical Prostatectomy and Metastasis-Directed Radiotherapy in Oligometastatic Prostate Cancer Patients: A Multicenter, Three-Arm, Open-Label, Randomized Controlled Phase II Clinical Trial
Latest Information Update: 01 Apr 2026
At a glance
- Drugs Rezvilutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms OMPC-RPM
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 01 Apr 2026 New trial record